Clinical Trial Update: Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating intravitreal SKG0106 for neovascular age-related macular degeneration is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• SKG0106

Snippet

Sponsor: Skyline Therapeutics (US) Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: RECRUITING